Powerpoint

Comments

Transcription

Powerpoint
Effect of Pravastatin on Cardiovascular Events in People
With Chronic Kidney Disease
by Marcello Tonelli, Chris Isles, Gary C. Curhan, Andrew Tonkin, Marc A. Pfeffer,
James Shepherd, Frank M. Sacks, Curt Furberg, Stuart M. Cobbe, John Simes,
Timothy Craven, and Malcolm West
Circulation
Volume 110(12):1557-1563
September 21, 2004
Copyright © American Heart Association, Inc. All rights reserved.
Figure 1. Unadjusted incidence of clinical outcomes by level of kidney function and treatment
group in subjects with known coronary disease at baseline.
Marcello Tonelli et al. Circulation. 2004;110:1557-1563
Copyright © American Heart Association, Inc. All rights reserved.
Figure 2. Adjusted risk of cardiovascular outcomes associated with a unit decrease in renal
function.
Marcello Tonelli et al. Circulation. 2004;110:1557-1563
Copyright © American Heart Association, Inc. All rights reserved.
Figure 3. Adjusted effect of pravastatin on cardiovascular outcomes by level of kidney function
as defined by estimated GFR (using Cockcroft-Gault formula).
Marcello Tonelli et al. Circulation. 2004;110:1557-1563
Copyright © American Heart Association, Inc. All rights reserved.
Figure 4. Adjusted effect of pravastatin on cardiovascular outcomes by level of kidney function
as defined by estimated GFR (using MDRD-GFR equation).
Marcello Tonelli et al. Circulation. 2004;110:1557-1563
Copyright © American Heart Association, Inc. All rights reserved.

Similar documents